InCytu, Inc: A therapeutic device engineering company

InCytu, Inc. is a therapeutic device engineering company developing immunotherapeutic and tissue regeneration products to transform personalized medicine. Founded in 2007 and lead by a strong management team, the cornerstone of InCytu’s transformative technology platform was developed by Prof. David Mooney at Harvard University. The Company’s first products revolve around the Cellarium™ system, a family of intelligent bioresorbable materials which are formulated and programmed to manipulate the immune system or rapidly heal and regenerate damaged or diseased tissue.

InCytu has focused its development program on its i-BD Active Specific Immunotherapy Cancer Vaccine.  The first application of this dendritic cell mediated vaccine will be to treat late stage melanoma patients.

 InCytu’s product pipeline also includes applications of the Cellarium™ platform to accelerate the revascularization and regeneration of soft tissue for military and civilian populations. In April 2008, InCytu was selected to be part of the Armed Forces Institute for Regenerative Medicine (AFIRM) consortium in order to provide accelerated tissue repair and regeneration for our injured war fighters.

In Cytu, Inc. is a privately-held corporation with its primary operations in Rhode Island.

For Clinicians

Cellarium™ devices are based on bioresorbable polymer scaffolds containing bioactive factors that are preprogrammed to function or be released in a temporally controlled fashion. This proprietary technology enables the unprecedented control of in vivo cell selection, gathering, proliferation, maturation and enhanced, functional, cellular integration within the body’s native processes and tissues.

 The characterized and validated immunotherapeutic product has demonstrated reproducible efficacy in a wide array of clinically relevant preclinical models. Portions of the development work is published in peer reviewed journals.

The Cellarium Immunotherapeutic product (Cancer Vaccine) is comprised of four active components:

  • A PLG resorbable porous scaffold 
  • A cytokine to specifically attract dendritic cells
  • An adjuvant and
  • Markers for the tumor to be targeted

When placed subcutaneously the 8.5 mm x 2 mm thick disk attracts dendritic cells (DC) into the porous device where the DCs are activated through contact with the adjuvant and the tumor antigens.  The Cellarium then enables the DCs to leave and migrate to the lymph nodes and the PLG scaffold dissolves like resorbable sutures.